Inventor
Ravindra Majeti
Inventor
Palo Alto, CA, US
Overview
Patents· 26 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Kprimary
C07KPeptides21%
A61KPreparations for medical, dental or toiletry purposes19%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations17%
G01NInvestigating or analysing materials by determining their chemical or physical properties15%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms12%
C12NMicroorganisms or enzymes12%
Y02ATechnologies for adaptation to climate change3%
PatentTitleYear
11,104,731Compositions for achieving therapeutically effective doses of anti-CD47 agents202111,072,655Markers of acute myeloid leukemia stem cells202111,014,985Humanized and chimeric monoclonal antibodies to CD47202110,995,152Modified immunoglobulin hinge regions to reduce hemagglutination202110,942,185Therapeutic and diagnostic methods for manipulating phagocytosis through calreticulin and low density lipoprotein-related receptor202110,662,242Markers of acute myeloid leukemia stem cells202010,640,561Methods for manipulating phagocytosis mediated by CD47202010,487,150SIRP alpha-antibody fusion proteins201910,301,387Methods for achieving therapeutically effective doses of anti-CD47 agents201910,087,257SIRP alpha-antibody fusion proteins201810,040,862Humanized and chimeric monoclonal antibodies to CD9920189,796,781'Markers of acute myeloid leukemia stem cells'20179,765,143'Methods for manipulating phagocytosis mediated by CD47'20179,624,305'Methods of manipulating phagocytosis mediated by CD47'20179,623,079'Methods for achieving therapeutically effective doses of anti-CD47 agents for treating cancer'20179,611,329'Methods of manipulating phagocytosis mediated by CD47'20179,605,076'Methods of manipulating phagocytosis mediated by CD47'20179,493,575'Methods for manipulating phagocytosis mediated by CD47'20169,399,682'Methods for manipulating phagocytosis mediated by CD47'20169,382,320'Humanized and chimeric monoclonal antibodies to CD47'20169,193,955'Markers of acute myeloid leukemia stem cells'20159,017,675'Humanized and chimeric monoclonal antibodies to CD47'20158,758,750'Synergistic anti-CD47 therapy for hematologic cancers'20148,709,429'Markers of acute myeloid leukemia stem cells'20148,562,997'Methods of treating acute myeloid leukemia by blocking CD47'20138,361,736'Ex vivo methods for targeting or depleting acute myeloid leukemia cancer stem cells'2013Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2013–2021Patents assigned to UNIV LELAND STANFORD JUNIOR (26)· patent assignee history
2013–2014Patents assigned to MAJETI RAVINDRA (3)· patent assignee history
2013–2014Patents assigned to WEISSMAN IRVING L (3)· patent assignee history
2013–2014Patents assigned to CHAO MARK P (2)· patent assignee history
2013–2016Based in Stanford, CA, US· patent location history
2014Patents assigned to ALIZADEH ARASH ASH (1)· patent assignee history
2015Based in Standford, CA, US· patent location history
2017–2021Based in Palo Alto, CA, US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| UNIV LELAND STANFORD JUNIOR | 26 | 2013–2021 |
| MAJETI RAVINDRAself | 3 | 2013–2014 |
| WEISSMAN IRVING L | 3 | 2013–2014 |
| CHAO MARK P | 2 | 2013–2014 |
| ALIZADEH ARASH ASH | 1 | 2014 |
Locations
| Location | Patents | Span |
|---|---|---|
| Palo Alto, California, US | 17 | 2017–2021 |
| Stanford, California, US | 8 | 2013–2016 |
| Standford, California, US | 1 | 2015 |